H Lundbeck A/S - Asset Resilience Ratio
H Lundbeck A/S (HLUN-A) has an Asset Resilience Ratio of -0.56% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read H Lundbeck A/S (HLUN-A) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2022)
This chart shows how H Lundbeck A/S's Asset Resilience Ratio has changed over time. See H Lundbeck A/S net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down H Lundbeck A/S's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see HLUN-A market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 0% |
| Short-term Investments | Dkr-208.00 Million | -0.56% |
| Total Liquid Assets | Dkr-208.00 Million | -0.56% |
Asset Resilience Insights
- Limited Liquidity: H Lundbeck A/S maintains only -0.56% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
H Lundbeck A/S Industry Peers by Asset Resilience Ratio
Compare H Lundbeck A/S's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for H Lundbeck A/S (2008–2022)
The table below shows the annual Asset Resilience Ratio data for H Lundbeck A/S.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | -0.52% | Dkr-195.00 Million ≈ $-30.51 Million |
Dkr37.45 Billion ≈ $5.86 Billion |
-0.13pp |
| 2021-12-31 | -0.39% | Dkr-134.00 Million ≈ $-20.97 Million |
Dkr34.65 Billion ≈ $5.42 Billion |
-0.10pp |
| 2020-12-31 | -0.29% | Dkr-104.00 Million ≈ $-16.27 Million |
Dkr36.03 Billion ≈ $5.64 Billion |
-0.30pp |
| 2019-12-31 | 0.01% | Dkr4.00 Million ≈ $625.83K |
Dkr35.76 Billion ≈ $5.59 Billion |
-13.16pp |
| 2018-12-31 | 13.17% | Dkr3.03 Billion ≈ $474.07 Million |
Dkr23.01 Billion ≈ $3.60 Billion |
+5.46pp |
| 2017-12-31 | 7.70% | Dkr1.52 Billion ≈ $238.13 Million |
Dkr19.76 Billion ≈ $3.09 Billion |
+7.62pp |
| 2016-12-31 | 0.08% | Dkr17.00 Million ≈ $2.66 Million |
Dkr20.21 Billion ≈ $3.16 Billion |
+0.00pp |
| 2015-12-31 | 0.08% | Dkr17.00 Million ≈ $2.66 Million |
Dkr21.32 Billion ≈ $3.34 Billion |
+0.01pp |
| 2014-12-31 | 0.07% | Dkr18.00 Million ≈ $2.82 Million |
Dkr25.64 Billion ≈ $4.01 Billion |
-4.34pp |
| 2013-12-31 | 4.41% | Dkr1.04 Billion ≈ $163.03 Million |
Dkr23.65 Billion ≈ $3.70 Billion |
-0.49pp |
| 2012-12-31 | 4.89% | Dkr1.05 Billion ≈ $165.06 Million |
Dkr21.56 Billion ≈ $3.37 Billion |
-2.30pp |
| 2011-12-31 | 7.19% | Dkr1.48 Billion ≈ $230.93 Million |
Dkr20.53 Billion ≈ $3.21 Billion |
+6.89pp |
| 2010-12-31 | 0.30% | Dkr54.00 Million ≈ $8.45 Million |
Dkr18.00 Billion ≈ $2.82 Billion |
-0.04pp |
| 2009-12-31 | 0.34% | Dkr59.00 Million ≈ $9.23 Million |
Dkr17.13 Billion ≈ $2.68 Billion |
-7.23pp |
| 2008-12-31 | 7.58% | Dkr955.00 Million ≈ $149.42 Million |
Dkr12.61 Billion ≈ $1.97 Billion |
-- |
About H Lundbeck A/S
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat maj… Read more